Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients

Acute venous thromboembolism (VTE) is a serious and potentially fatal disorder, which often complicates the course of hospitalized medical patients. This is particularly true for carriers of malignant diseases. While the introduction of thromboprophylactic measures has probably affected the occurrence of postoperative VTE, there is an increasing awareness of the importance of medical conditions in determining thromboembolic events. Simple and clinically relevant risk assessment models are available to facilitate VTE risk assessment in hospitalized medical patients. Their validation in prospective studies is in progress. Randomized controlled clinical trials have consistently documented the efficacy of heparins and fondaparinux for prevention of VTE in hospitalized medical patients with a minimal haemorrhagic risk. Recognition of the incidence and clinical importance of thrombosis will probably encourage more widespread use of antithrombotic prophylaxis in medical patients and especially in some particular types of malignancies.

[1]  Gary H Lyman,et al.  Development and validation of a predictive model for chemotherapy-associated thrombosis. , 2008, Blood.

[2]  Samuel Z Goldhaber,et al.  Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study , 2008, The Lancet.

[3]  J. Jansson,et al.  Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta‐analysis , 2007, Journal of internal medicine.

[4]  J. Douketis,et al.  The Risk for Fatal Pulmonary Embolism after Discontinuing Anticoagulant Therapy for Venous Thromboembolism , 2007, Annals of Internal Medicine.

[5]  Gary H Lyman,et al.  American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Nokes,et al.  Derivation and Validation of a Prediction Tool for Venous Thromboembolism: A VERITY Registry Study. , 2007 .

[7]  J. Donovan,et al.  Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. , 2007, Clinical therapeutics.

[8]  H. Büller,et al.  Prevention of catheter‐related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo‐controlled study , 2007, Journal of thrombosis and haemostasis : JTH.

[9]  A. Turpie,et al.  Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. , 2007, Chest.

[10]  R. Milani,et al.  Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients , 2007, Vascular health and risk management.

[11]  H. Krum,et al.  Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials. , 2007, Archives of internal medicine.

[12]  R. Goldberg,et al.  Venous thromboembolism in the outpatient setting. , 2007, Archives of internal medicine.

[13]  J. Hirsh,et al.  Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery , 2007, Journal of thrombosis and haemostasis : JTH.

[14]  A. Tefferi,et al.  Clinical correlates of JAK2V617F allele burden in essential thrombocythemia , 2007, Cancer.

[15]  A. Tefferi,et al.  Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. , 2007, Seminars in thrombosis and hemostasis.

[16]  J. Hanley,et al.  Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study. , 2007, The Lancet. Oncology.

[17]  C. Kase,et al.  The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison , 2007, The Lancet.

[18]  C. Francis Prophylaxis for Thromboembolism in Hospitalized Medical Patients , 2007 .

[19]  M. Rodger,et al.  The effect of low‐molecular‐weight heparin on cancer survival. A systematic review and meta‐analysis of randomized trials , 2007, Journal of thrombosis and haemostasis : JTH.

[20]  P. Romundstad,et al.  Incidence and mortality of venous thrombosis: a population‐based study , 2007, Journal of thrombosis and haemostasis : JTH.

[21]  A. Khorana,et al.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy , 2007, Journal of thrombosis and haemostasis : JTH.

[22]  J. Douketis,et al.  Meta-analysis: Anticoagulant Prophylaxis to Prevent Symptomatic Venous Thromboembolism in Hospitalized Medical Patients , 2007, Annals of Internal Medicine.

[23]  A. Shorr,et al.  Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: A metaanalysis. , 2007, Chest.

[24]  G. Tiscia,et al.  The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis , 2007, Journal of thrombosis and haemostasis : JTH.

[25]  V. Hach-Wunderle,et al.  An Evaluation of Venous Thromboembolic Risk in Acutely Ill Medical Patients Immobilized at Home: The AT-HOME Study , 2007, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[26]  H. Chew,et al.  Incidence of venous thromboembolism and the impact on survival in breast cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Panju,et al.  Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. , 2007, Thrombosis research.

[28]  A. Encke,et al.  [Preventing venous thromboembolism]. , 2007, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[29]  P. Novotny,et al.  Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. , 2007, Mayo Clinic proceedings.

[30]  P. Mannucci,et al.  Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis , 2006, Hepatology.

[31]  D. Gaitini,et al.  Prevalence of Upper Extremity Deep Venous Thrombosis Diagnosed by Color Doppler Duplex Sonography in Cancer Patients With Central Venous Catheters , 2006, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[32]  M. Samama,et al.  An update on prevention of venous thromboembolism in hospitalized acutely ill medical patients , 2006, Thrombosis journal.

[33]  M. Levine,et al.  Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  H. Chew,et al.  Incidence of venous thromboembolism and its effect on survival among patients with common cancers. , 2006, Archives of internal medicine.

[35]  G. Steger,et al.  Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  M. Prins,et al.  Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial , 2006, BMJ : British Medical Journal.

[37]  J. Labarère,et al.  Determining Indications for Care Common to Competing Guidelines by Using Classification Tree Analysis: Application to the Prevention of Venous Thromboembolism in Medical Inpatients , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[38]  P. Prandoni,et al.  Cancer and venous thromboembolism. , 1996, Seminars in thrombosis and hemostasis.

[39]  G. Geroulakos,et al.  Prevention and Treatment of Venous Thromboembolism , 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[40]  P. Stein,et al.  Incidence of venous thromboembolism in patients hospitalized with cancer. , 2006, The American journal of medicine.

[41]  J. Kahan,et al.  An electronic tool for venous thromboembolism prevention in medical and surgical patients. , 2006, Haematologica.

[42]  A. Khorana,et al.  Risk factors for chemotherapy‐associated venous thromboembolism in a prospective observational study , 2005, Cancer.

[43]  A. Turpie,et al.  Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients , 2005, Thrombosis and Haemostasis.

[44]  S. Yale,et al.  Risk assessment model for venothromboembolism in post-hospitalized patients. , 2005, International angiology : a journal of the International Union of Angiology.

[45]  J. Olsen,et al.  The risk of a second cancer after hospitalisation for venous thromboembolism , 2005, British Journal of Cancer.

[46]  H. Chew,et al.  Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. , 2005, Archives of internal medicine.

[47]  I. Mahé,et al.  Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study , 2005, European Journal of Clinical Pharmacology.

[48]  D. Anderson,et al.  Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Armando Santoro,et al.  Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  P. Langhorne,et al.  Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review , 2005, Thrombosis and Haemostasis.

[51]  J. Bergmann,et al.  Venous thromboembolism in the medically ill patient: a call to action , 2005, International journal of clinical practice.

[52]  D. Hayoz,et al.  Venous thromboembolism prophylaxis in acutely ill medical patients: definite need for improvement , 2005, Journal of internal medicine.

[53]  Susanne M. Smorenburg,et al.  The effect of low molecular weight heparin on survival in patients with advanced malignancy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  M. Prins,et al.  Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  E. Medico,et al.  The MET oncogene drives a genetic programme linking cancer to haemostasis , 2005, Nature.

[56]  F. Rosendaal,et al.  Malignancies, prothrombotic mutations, and the risk of venous thrombosis. , 2005, JAMA.

[57]  Marilyn D Paterno,et al.  Electronic alerts to prevent venous thromboembolism among hospitalized patients. , 2005, The New England journal of medicine.

[58]  A. Leizorovicz,et al.  Preventing Venous Thromboembolism in Medical Patients , 2004, Circulation.

[59]  S. Humphries,et al.  Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway , 2004, Journal of thrombosis and haemostasis : JTH.

[60]  M. Cushman,et al.  Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score , 2004, Journal of thrombosis and haemostasis : JTH.

[61]  Clifford W Colwell,et al.  Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[62]  S. Goldhaber,et al.  Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients , 2004, Circulation.

[63]  S. Deitcher,et al.  The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma , 2004, Cancer.

[64]  A. Unal,et al.  A randomized clinical trial of combination chemotherapy with and without low‐molecular‐weight heparin in small cell lung cancer , 2004, Journal of thrombosis and haemostasis : JTH.

[65]  M. Müller,et al.  Complicated Case of Left Ventricular Echinococcosis , 2004 .

[66]  J. Murchison,et al.  Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study , 2004, British Journal of Cancer.

[67]  T. M. Norris,et al.  Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin , 2004, Thrombosis and Haemostasis.

[68]  Michael Thomas,et al.  Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  A. Turpie,et al.  Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. , 2004, Archives of internal medicine.

[70]  P. Lønning,et al.  Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study , 2003, BMJ : British Medical Journal.

[71]  S. Goldhaber,et al.  A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. , 2004, The American journal of cardiology.

[72]  G. Agnelli,et al.  Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  R. Wolff,et al.  Venous thrombosis in cancer patients: insights from the FRONTLINE survey. , 2003, The oncologist.

[74]  C. Witt,et al.  Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. , 2003, American heart journal.

[75]  J. Heit,et al.  Risk factors for venous thromboembolism. , 2003, Clinics in chest medicine.

[76]  L. Melton,et al.  Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. , 2002, Archives of internal medicine.

[77]  P. Reitsma,et al.  Genetic risk factors for venous thrombosis. , 2000, Molecular genetics and metabolism.

[78]  S. Schulman,et al.  Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. , 2000, The New England journal of medicine.

[79]  E. Oger Incidence of Venous Thromboembolism: A Community-based Study in Western France , 2000, Thrombosis and Haemostasis.

[80]  W M O'Fallon,et al.  Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. , 2000, Archives of internal medicine.

[81]  Lain,et al.  A COMPARISON OF ENOXAPARIN WITH PLACEBO FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS , 2000 .

[82]  M. Cucherat,et al.  Prevention of Venous Thromboembolism in Internal Medicine with Unfractionated or Low-molecular-weight Heparins: A Meta-analysis of Randomised Clinical Trials , 2000, Thrombosis and Haemostasis.

[83]  A. Turpie,et al.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.

[84]  A A Rimm,et al.  Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. , 1999, Medicine.

[85]  J. Olsen,et al.  The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. , 1998, The New England journal of medicine.

[86]  L. Welin,et al.  Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913'. , 1997, Archives of internal medicine.

[87]  F. Rosendaal Risk factors for venous thrombosis: prevalence, risk, and interaction. , 1997, Seminars in hematology.

[88]  B. Zee,et al.  Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  J. Bergmann,et al.  Heparin prophylaxis in bedridden patients , 1996, The Lancet.

[90]  B. Gårdlund,et al.  Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases , 1996, The Lancet.

[91]  R. Rosell,et al.  Upper Extremity Deep Venous Thrombosis in Cancer Patients with Venous Access Devices - Prophylaxis with a Low Molecular Weight Heparin (Fragmin) , 1996, Thrombosis and Haemostasis.

[92]  B. Gärdlund Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group. , 1996, Lancet.

[93]  D. Hosmer,et al.  The prevalence of risk factors for venous thromboembolism among hospital patients. , 1992, Archives of internal medicine.

[94]  B. Lindblad,et al.  A prospective study of the incidence of deep‐vein thrombosis within a defined urban population , 1992, Journal of internal medicine.

[95]  Venous thromboembolism and cancer. , 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[96]  P. Benotti,et al.  Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. , 1990, Annals of internal medicine.

[97]  B. Modan,et al.  Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. , 1982, Annals of internal medicine.

[98]  E. Pollak,et al.  Fatal Pulmonary Embolism in Cancer Patients: Is Heparin Prophylaxis Justified , 1980, Southern medical journal.

[99]  Small subcutaneous doses of heparin in prevention of venous thrombosis. , 1973, The New England journal of medicine.